209 related articles for article (PubMed ID: 29509240)
61. Dihydroartemisinin potentiates the anticancer effect of cisplatin via mTOR inhibition in cisplatin-resistant ovarian cancer cells: involvement of apoptosis and autophagy.
Feng X; Li L; Jiang H; Jiang K; Jin Y; Zheng J
Biochem Biophys Res Commun; 2014 Feb; 444(3):376-81. PubMed ID: 24462866
[TBL] [Abstract][Full Text] [Related]
62. PDCD1 strengthens the sensitivity of ovarian cancer to cisplatin chemotherapy by promoting apoptosis.
Li Q; Gao JF; Qi BL
J BUON; 2017; 22(3):746-756. PubMed ID: 28730785
[TBL] [Abstract][Full Text] [Related]
63. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
Liu JT; Li WC; Gao S; Wang F; Li XQ; Yu HQ; Fan LL; Wei W; Wang H; Sun GP
Clin Lung Cancer; 2015 Sep; 16(5):e55-66. PubMed ID: 25979647
[TBL] [Abstract][Full Text] [Related]
64. Long non-coding RNA ENST00000457645 reverses cisplatin resistance in CP70 ovarian cancer cells.
Yan H; Xia JY; Feng FZ
Genet Mol Res; 2017 Jan; 16(1):. PubMed ID: 28128423
[TBL] [Abstract][Full Text] [Related]
65. Long noncoding RNA growth arrest-specific 5 facilitates glioma cell sensitivity to cisplatin by suppressing excessive autophagy in an mTOR-dependent manner.
Huo JF; Chen XB
J Cell Biochem; 2019 Apr; 120(4):6127-6136. PubMed ID: 30317677
[TBL] [Abstract][Full Text] [Related]
66. Cisplatin induces protective autophagy through activation of BECN1 in human bladder cancer cells.
Lin JF; Lin YC; Tsai TF; Chen HE; Chou KY; Hwang TI
Drug Des Devel Ther; 2017; 11():1517-1533. PubMed ID: 28553083
[TBL] [Abstract][Full Text] [Related]
67. Luteolin sensitizes the antitumor effect of cisplatin in drug-resistant ovarian cancer via induction of apoptosis and inhibition of cell migration and invasion.
Wang H; Luo Y; Qiao T; Wu Z; Huang Z
J Ovarian Res; 2018 Nov; 11(1):93. PubMed ID: 30454003
[TBL] [Abstract][Full Text] [Related]
68. Apoptosis as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell lines.
Gibb RK; Taylor DD; Wan T; O'Connor DM; Doering DL; Gerçel-Taylor C
Gynecol Oncol; 1997 Apr; 65(1):13-22. PubMed ID: 9103385
[TBL] [Abstract][Full Text] [Related]
69. LncRNA RP11-551L14.4 suppresses breast cancer development by inhibiting the expression of miR-4472.
Wang B; Chen H; Yang R; Xing L; Chen C; Chen J
PeerJ; 2022; 10():e14482. PubMed ID: 36523479
[TBL] [Abstract][Full Text] [Related]
70. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner.
Yan X; Fraser M; Qiu Q; Tsang BK
Gynecol Oncol; 2006 Aug; 102(2):348-55. PubMed ID: 16545436
[TBL] [Abstract][Full Text] [Related]
71. BNIP3 contributes to cisplatin-induced apoptosis in ovarian cancer cells.
Jia J; Yang X; Zhao Q; Ying F; Cai E; Sun S; He X
FEBS Open Bio; 2020 Aug; 10(8):1463-1473. PubMed ID: 32412667
[TBL] [Abstract][Full Text] [Related]
72. [Reversal of drug resistance in human ovarian cancer cells by wild-type PTEN gene and its mechanisms].
Wu HJ; Wu HT; Weng DH; Xing H; Lu YP; Ma D
Zhonghua Fu Chan Ke Za Zhi; 2007 Sep; 42(9):612-6. PubMed ID: 17983517
[TBL] [Abstract][Full Text] [Related]
73. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
Ma JJ; Chen BL; Xin XY
Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744
[TBL] [Abstract][Full Text] [Related]
74. Depletion of the lncRNA RP11-567G11.1 inhibits pancreatic cancer progression.
Huang R; Nie W; Yao K; Chou J
Biomed Pharmacother; 2019 Apr; 112():108685. PubMed ID: 30802827
[TBL] [Abstract][Full Text] [Related]
75. The lncRNA HULC functions as an oncogene by targeting ATG7 and ITGB1 in epithelial ovarian carcinoma.
Chen S; Wu DD; Sang XB; Wang LL; Zong ZH; Sun KX; Liu BL; Zhao Y
Cell Death Dis; 2017 Oct; 8(10):e3118. PubMed ID: 29022892
[TBL] [Abstract][Full Text] [Related]
76. Chloroquine enhances the efficacy of cisplatin by suppressing autophagy in human adrenocortical carcinoma treatment.
Qin L; Xu T; Xia L; Wang X; Zhang X; Zhang X; Zhu Z; Zhong S; Wang C; Shen Z
Drug Des Devel Ther; 2016; 10():1035-45. PubMed ID: 27022243
[TBL] [Abstract][Full Text] [Related]
77. Inhibitor of signal transducer and activator of transcription 3 (STAT3) suppresses ovarian cancer growth, migration and invasion and enhances the effect of cisplatin in vitro.
Tang YJ; Sun ZL; Wu WG; Xing J; He YF; Xin DM; Han P
Genet Mol Res; 2015 Mar; 14(1):2450-60. PubMed ID: 25867391
[TBL] [Abstract][Full Text] [Related]
78. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
79. MicroRNA-143 Sensitizes Cervical Cancer Cells to Cisplatin: a Promising Anticancer Combination Therapy.
Esfandyari YB; Doustvandi MA; Amini M; Baradaran B; Zaer SJ; Mozammel N; Mohammadzadeh M; Mokhtarzadeh A
Reprod Sci; 2021 Jul; 28(7):2036-2049. PubMed ID: 33569751
[TBL] [Abstract][Full Text] [Related]
80. LncRNA RP11-79H23.3 Functions as a Competing Endogenous RNA to Regulate PTEN Expression through Sponging hsa-miR-107 in the Development of Bladder Cancer.
Chi H; Yang R; Zheng X; Zhang L; Jiang R; Chen J
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30149689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
